# US 2011/0300224 A1 · Taste masked dosage form of pharmaceutically acceptable salt of escitalopram

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0300224 A1
- Document ID: US20110300224A1
- Status: Published application
- Kind: A1
- Application number: 13/125,736
- Filed: 2009-12-11
- Published: 2011-12-08
- Earliest claimed: 2008-10-23
- Assignees: Genepharm A.E.
- Inventors: Deepak Murpani; Alexaki Pandora
- Web page: https://patentgrep.com/patent/US20110300224A1

## CPC

- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 9/1676: {having a drug-free core with discrete complete coating layer containing drug (adsorbates of liquid drug formulations on inert powders without simultaneous granulation step A61K9/141; with further drug-free outer coating A61K9/5078; drug conjugated to non-active particles A61K47/6921)}
- A61K 9/5078: {with drug-free core}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A taste masked dosage form of pharmaceutical acceptable salt of escitalopram comprising (a) resin complex of pharmaceutical acceptable salt of escitalopram and cationic exchange resin or adsorbing or coating non-pareil seeds or inert particles with a mixture of pharmaceutically acceptable salt of escitalopram, cationic polymer and optionally other polymer(s) or loading non-pareil seeds or inert particles with pharmaceutically salt of escitalopram followed by polymer coating with cationic polymer and optionally other polymer(s); and (b) at least one pharmaceutical excipient.

## Claims

### Claim 1

A taste masked resinate comprising a pharmaceutically acceptable salt of escitalopram complexed with a cationic ion exchange resin.

### Claim 2 (depends on 1)

A taste masked dosage form comprising a taste masked resinate as claimed in claim 1 and at least one pharmaceutical excipient.

### Claim 3 (depends on 2)

The taste masked dosage form as claimed in claim 2, selected from a tablet, a soluble tablet, sprinkle granules or powder for reconstitution in a suspension, a rapidly disintegrating tablet, an orally disintegrating tablet, a rapidly disintegrating film, an orally disintegrating powder for capsules, suspension or sachets, an effervescent tablet, a chewable tablet, a water dispersible tablet, an orodispersible tablet, a chewing gum and a suspension.

### Claim 4 (depends on 3)

The taste masked dosage form as claimed in claim 3, wherein the dosage form is an orally disintegrating tablet.

### Claim 5 (depends on 2)

The taste masked dosage form as claimed in claim 2, wherein the pharmaceutical excipient is selected from diluents, binders, lubricants, disintegrants, flavoring agents, coloring agents, stabilizers, surfactants, glidants, plasticizers, preservatives and sweeteners.

### Claim 6

A taste masked dosage form of a pharmaceutically acceptable salt of escitalopram obtained by adsorbing or coating non-pareil seeds or inert particles with a mixture of a pharmaceutically acceptable salt of escitalopram, cationic polymer and optionally other polymer(s).

### Claim 7 (depends on 6)

The taste masked dosage form as claimed in claim 6, wherein the cationic polymer is based on dimethylaminoethyl methacrylate and neutral methacrylates.

### Claim 8 (depends on 6)

The taste masked dosage form as claimed in claim 6, wherein the other polymer(s) is selected from the group consisting of ethylcellulose, cellulose acetate, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, and hydroxyethyl cellulose.

### Claim 9 (depends on 6)

The taste masked dosage form as claimed in claim 6, obtained by further adding at least one pharmaceutical excipient and compressing into tablets.

### Claim 10 (depends on 9)

The taste masked dosage form as claimed in claim 9, wherein the dosage form is selected from a tablet, soluble tablet, sprinkle granules or powder for reconstitution in a suspension, a rapidly disintegrating tablet, an orally disintegrating tablet, a rapidly disintegrating film, an orally disintegrating powder for capsules, suspension or sachets, an effervescent tablet, a chewable tablet, a water dispersible tablet, an orodispersible tablet, a chewing gum and a suspension.

### Claim 11 (depends on 10)

The taste masked dosage form as claimed in claim 10, wherein the dosage form is an orally disintegrating tablet.

### Claim 12

A taste masked dosage form of a pharmaceutically acceptable salt of escitalopram obtained by loading a pharmaceutically acceptable salt of escitalopram on non-pareil seeds or inert particles followed by coating with a cationic polymer and optionally other polymer(s).

### Claim 13 (depends on 12)

The taste masked dosage form as claimed in claim 12, wherein the catonic polymer is based on dimethylaminoethyl methacrylate and neutral methacrylates.

### Claim 14 (depends on 12)

The taste masked dosage form as claimed in claim 12, wherein the other polymer(s) is selected from the group consisting of ethylcellulose, cellulose acetate, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, and hydroxyethyl cellulose.

### Claim 15 (depends on 12)

The taste masked dosage form as claimed in claim 12, obtained by further adding at least one pharmaceutical excipient and compressing into tablets.

### Claim 16 (depends on 15)

The taste masked dosage form as claimed in claim 15, wherein the pharmaceutical excipient is selected from diluents, binders, lubricants, disintegrants, flavoring agents, coloring agents, stabilizers, surfactants, glidants, plasticizers, preservatives and sweeteners.

### Claim 17 (depends on 16)

The taste masked dosage form as claimed in claim 16, wherein the dosage form is selected from a tablet, a soluble tablet, sprinkle granules or powder for reconstitution in a suspension, a rapidly disintegrating tablet, an orally disintegrating tablet, a rapidly disintegrating film, an orally disintegrating powder for capsules, suspension or sachets, an effervescent tablet, a chewable tablet, a water dispersible tablet, an orodispersible tablet, a chewing gum and a suspension.

### Claim 18 (depends on 17)

The taste masked dosage form as claimed in claim 17, wherein the dosage form is an orally disintegrating tablet.

### Claim 19

A taste masked granule of a pharmaceutically acceptable salt of escitalopram comprising the pharmaceutically acceptable salt of escitalopram complexed with a cationic ion exchange resin and at least one pharmaceutical excipient.

### Claim 20 (depends on 19)

The taste masked granule as claimed in claim 19, wherein the pharmaceutical excipient is selected from diluents, binders, lubricants, disintegrants, flavoring agents, coloring agents, stabilizers, surfactants, glidants, plasticizers, preservatives and sweeteners.

### Claim 21

A taste masked granule of a pharmaceutically acceptable salt of escitalopram obtained by adsorbing or coating non-pareil seeds or inert particles with a mixture of a pharmaceutically acceptable salt of escitalopram, cationic polymer and optionally other polymer(s).

### Claim 22 (depends on 21)

The taste masked granule as claimed in claim 21, wherein the catonic polymer is based on dimethylaminoethyl methacrylate and neutral methacrylates.

### Claim 23 (depends on 21)

The taste masked granule as claimed in claim 21, wherein the other polymer(s) is selected from ethylcellulose, cellulose acetate, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, and hydroxyethyl cellulose.

### Claim 24

A taste masked orally disintegrating tablet of escitalopram oxalate comprising:
(i) a complex of escitalopram oxalate with a cationic ion exchange resin; and
(ii) at least one pharmaceutical excipient.

### Claim 25 (depends on 24)

The taste masked dosage form as claimed in claim 24, wherein the pharmaceutical excipient is selected from diluents, binders, lubricants, disintegrants, flavoring agents, coloring agents, stabilizers, surfactants, glidants, plasticizers, preservatives and sweeteners.

### Claim 26

A taste masked orally disintegrating tablet of escitalopram oxalate comprising
(i) non-pareil seeds or inert particles coated or adsorbed with a mixture of escitalopram oxalate, cationic polymer and optionally other polymer(s); and
(ii) at least one pharmaceutical excipient.

### Claim 27 (depends on 26)

The taste masked dosage form as claimed in claim 26, wherein the catonic polymer is based on dimethylaminoethyl methacrylate and neutral methacrylates.

### Claim 28 (depends on 26)

The taste masked dosage form as claimed in claim 26, wherein the other polymer(s) is selected from ethylcellulose, cellulose acetate, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, and hydroxyethyl cellulose.

### Claim 29

A taste masked dosage form of escitalopram oxlate obtained by loading escitalopram oxalate on non-pareil seeds or inert particles followed by coating with a cationic polymer and optionally other polymer(s).

### Claim 30 (depends on 29)

The taste masked dosage form as claimed in claim 29, wherein the catonic polymer is based on dimethylaminoethyl methacrylate and neutral methacrylates.

### Claim 31 (depends on 29)

The taste masked dosage form as claimed in claim 29, wherein the other polymer(s) is selected from ethylcellulose, cellulose acetate, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, and hydroxyethyl cellulose.

### Claim 32 (depends on 29)

The taste masked dosage form as claimed in claim 29, obtained by further adding at least one pharmaceutical excipient and compressing into tablets.

### Claim 33 (depends on 32)

The taste masked dosage form as claimed in claim 32, wherein the pharmaceutical excipient is selected from diluents, binders, lubricants, disintegrants, flavoring agents, coloring agents, stabilizers, surfactants, glidants, plasticizers, preservatives and sweeteners.

### Claim 34 (depends on 32)

The taste masked dosage form as claimed in claim 32, wherein the dosage form is selected from a tablet, a soluble tablet, sprinkle granules or powder for reconstitution in a suspension, a rapidly disintegrating tablet, an orally disintegrating tablet, a rapidly disintegrating film, an orally disintegrating powder for capsules, suspension or sachets, an effervescent tablet, a chewable tablet, a water dispersible tablet, an orodispersible tablet, a chewing gum and a suspension.

### Claim 35 (depends on 34)

The taste masked dosage form as claimed in claim 34, wherein the dosage form is an orally disintegrating tablet.

### Claim 36

A process for the preparation of a taste masked dosage form of a pharmaceutically acceptable salt of escitalopram comprising:
(a) complexing a pharmaceutically acceptable salt of escitalopram and a cationic ion exchange resin to prepare a resinate of the pharmaceutically acceptable salt of escitalopram or adsorbing/coating non-pareil seeds or inert particles with a mixture of a pharmaceutically acceptable salt of escitalopram, a cationic polymer and optionally other polymer(s) or loading non-pareil seeds or inert particles with a pharmaceutically acceptable salt of escitalopram followed by polymer coating with a cationic polymer and optionally other polymer(s);
(b) adding at least one pharmaceutical excipient; and
(c) compressing into tablets.

### Claim 37 (depends on 36)

The process for the preparation of a taste masked dosage form as claimed in claim 36, wherein the cationic polymer is based on dimethylaminoethyl methacrylate and neutral methacrylates.

### Claim 38 (depends on 36)

The process for the preparation of a taste masked dosage form as claimed in claim 36, wherein the pharmaceutical excipient is selected from diluents, binders, lubricants, disintegrants, flavoring agents, coloring agents, stabilizers, surfactants, glidants, plasticizers, preservatives and sweeteners.

### Claim 39

A process for the preparation of a taste masked dosage form of escitalopram oxalate comprising:
(a) complexing escitalopram oxalate and a cationic ion exchange resin to prepare a resinate of the escitalopram oxalate or adsorbing/coating non-pareil seeds or inert particles with a mixture of a pharmaceutically acceptable salt of escitalopram, a cationic polymer and optionally other polymer(s) or loading non-pareil seeds or inert particles with escitalopram oxalate followed by polymer coating with a cationic polymer and optionally other polymer(s);
(b) adding atleast at least one pharmaceutical excipient; and
(c) compressing into tablets.

### Claim 40 (depends on 39)

The process for the preparation of a taste masked dosage form as claimed in claim 39, wherein the cationic polymer is based on dimethylaminoethyl methacrylate and neutral methacrylates.

### Claim 41 (depends on 39)

The process for the preparation of a taste masked dosage form as claimed in claim 39, wherein the pharmaceutical excipient is selected from diluents, binders, lubricants, disintegrants, flavoring agents, coloring agents, stabilizers, surfactants, glidants, plasticizers, preservatives and sweeteners.
